Strategic partnerships Minerva Imaging has recently partnered with Debiopharm Group and TD2 Oncology, plus Thor Medical, signaling a strong appetite for collaborative programs to advance radiopharmaceutical development and lead-212 availability. This shows a ready channel for co-development deals, sponsored research, and joint ventures.

Expansion & M&A The company was acquired by Nordic Capital in 2025, indicating access to expanded capital, scale, and potential for accelerated growth initiatives. This environment creates opportunities to position advanced radiopharmaceutical services to support integration, portfolio expansion, and international scale projects.

BioTech capabilities With integrated CRO and CDMO services focused on targeted radionuclide therapies, in vivo imaging, and capabilities like Alpha-SPECT expansion, Minerva Imaging offers end‑to‑end translational research and manufacturing. Prospects exist to sell end-to-end radiopharmaceutical development, process optimization, and GMP manufacturing support.

Market demand signals Active engagement in oncology, cardiovascular disease models, and radiopharmaceutical therapy indicates rising demand for specialized preclinical to clinical translation. Target opportunities include bespoke toxicology, dosimetry, radiochemistry optimization, and regulatory readiness services for radionuclide drugs.

Leadership & growth New leadership appointments such as Head of Partnering & Business Strategy and ongoing participation in major conferences (AACR 2026) suggest a strategic emphasis on partnerships and business development. This presents a doorway to engage decision-makers on scalable collaboration frameworks and long‑term program support.